Prostate-Specific Antigen/Prostatic Acid Phosphatase Ratio Is Significant Prognostic Factor in Patients with Stage IV Prostate Cancer

Urology

Volumn 70, Issue 4, 2007, Pages 702-705

  Saito, Toshihiro ^a   Hara, Noboru ^a   Kitamura, Yasuo ^a   Komatsubara, Shuichi ^a  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENZYME IMMUNOASSAY; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIOIMMUNOASSAY; SURVIVAL RATE; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; HEMOGLOBINS; HUMANS; KAPLAN-MEIERS ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 35648953250     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.05.019     Document Type: Article

References (27)

1. Badalament R.A., and Drago J.R. Prostate cancer. Dis Mon 37 (1991) 199-268
2. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics 2001. CA Cancer J Clin 51 (2001) 15-36
3. Yoshimi I., and Sobue T. Current status and trends in cancer mortality in Japan. Jpn J Cancer Chemother 31 (2004) 832-839
4. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12 (2005) 46-61
5. Saito T., Kitamura Y., Komatsubara S., et al. Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. Asian J Androl 8 (2006) 555-561
6. Saito T., Kitamura Y., and Komatsubara S. Chemo-endocrine therapy for newly diagnosed stage D2 prostate cancer. Hinyokika Kiyo 51 (2005) 789-792
7. Mulders P.F., Dijkman G.A., Fernandez del Moral P., et al., Dutch Southeastern Urological Cooperative Group. Analysis of prognostic factors in disseminated prostatic cancer: an update. Cancer 65 (1990) 2758-2761
8. Eisenberger M.A., Crawford E.D., Wolf M., et al. Prognostic factors in stage D2 prostate cancer: important implications for future trials-results of a cooperative Intergroup study (INT 0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 21 (1994) 613-619
9. Vollmer R.T., Kantoff P.W., Dawson N.A., et al. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin Cancer Res 5 (1999) 831-837
10. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
11. Rozhansky F., Chen M.H., Cox M.C., et al. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106 (2006) 63-67
12. Hara N., Kitamura Y., Saito T., et al. Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian J Androl 8 (2006) 429-434
13. Roscigno M., Scattoni V., Bertini R., et al. Diagnosis of prostate cancer: state of the art. Minerva Urol Nefrol 56 (2004) 123-145
14. Varma M., Morgan M., Jasani M.B., et al. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol 118 (2002) 202-207
15. Goldstein N.S. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 117 (2002) 471-477
16. Kuriyama M., Akimoto S., Akaza H., et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn J Clin Oncol 22 (1992) 393-399
17. Jibiki K., Momura T., Demura R., et al. Fundamental and clinical studies on PAP "Eiken" kit. Clin Endocrinol 29 (1981) 1547-1552
18. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
19. Kuriyama M., Obata K., Miyagawa Y., et al. Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: an analysis of 749 cases. Int J Urol 3 (1996) 462-467
20. Moss D.W., Raymond F.D., and Wile D.B. Clinical and biological aspects of acid phosphatase. Crit Rev Clin Lab Sci 32 (1995) 431-467
21. Gutman E.B., Sproul E.E., and Gutman A.B. Significance of increased phosphatase activity at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28 (1936) 485-495
22. Huggins C., and Hodges C.V. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
23. Veeramani S., Yuan T.C., Chen S.J., et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 12 (2005) 805-822
24. Grande M., Carlstrom K., Lundh-Rozell B., et al. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma. Scand J Urol Nephrol 39 (2005) 393-398
25. Morote J., Vallejo C., and Lorente J.A. Clinical significance of inverted PSA/PAP ratio in prostate cancer patients. Int J Biol Markers 10 (1995) 58
26. Moul J.W., Connelly R.R., Perahia B., et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 159 (1998) 935-940
27. Saito T, Kitamura Y, and Komatsubara S: Prognosis of prostate cancer with elevated prostatic acid phosphatase Hinyokika Kiyo 52: 177-180, 2006.